Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8240123 | International Journal of Radiation Oncology*Biology*Physics | 2008 | 6 Pages |
Abstract
Independent significant predictors of DBF in our series included number of metastases (more than three), present or uncontrolled extracranial disease, and melanoma histologic characteristics. These factors were combined to identify a lower risk subgroup with significantly longer time to DBF. These patients may be candidates for initial localized treatment, reserving whole-brain radiation therapy for salvage. Patients in the higher risk group may be candidates for initial whole-brain radiation therapy or should be considered for clinical trials.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Stephen M. M.D., Ph.D., Barton L. M.D., Sharon A. M.D., Robert A. M.D., Ruby F. M.D., Ph.D., James M. M.D., Gretchen A. Ph.D., John B. M.D.,